Astellas Oncology adds value to its strategic alliances through its unique market position and expertise.
Astellas Oncology and Medivation commercialize XTANDI® (enzalutamide) in the United States.Visit Medivation
Astellas Oncology and Genentech, a member of the Roche Group, jointly market Tarceva® (erlotinib) in the United States.Visit Genentech
Mary Jo Struttmann
Executive Director of Alliance Management
Astellas Oncology and Dana-Farber Cancer Institute have formed a collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer.Visit Dana-Farber Cancer Institute
Astellas Oncology and the University of Texas MD Anderson Cancer Center are collaborating to research and develop a new treatment for patients with acute myeloid leukemia.Visit MD Anderson Cancer Center